Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer

BACKGROUND: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0–5-year and 5–10-year follow-up separately are more prognostic than a single signature optimised...

Descripción completa

Detalles Bibliográficos
Autores principales: Buus, Richard, Yeo, Belinda, Brentnall, Adam R., Klintman, Marie, Cheang, Maggie Chon U., Khabra, Komel, Sestak, Ivana, Gao, Qiong, Cuzick, Jack, Dowsett, Mitch
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122470/
https://www.ncbi.nlm.nih.gov/pubmed/30180877
http://dx.doi.org/10.1186/s13058-018-1040-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122470/
https://www.ncbi.nlm.nih.gov/pubmed/30180877
http://dx.doi.org/10.1186/s13058-018-1040-9

Ejemplares similares